πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 41 of 173

  1. US 10993930

    Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10988782

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10988748

    Compositions and methods for treating celiac sprue disease

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10987434

    Detection and treatment of caries and microcavities with nanoparticles

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10987373

    DNA origami nanostructures for treatment of acute kidney injury

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10988780

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10982231

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10980755

    LRH-1 modulators

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10981896

    Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10982232

    Diterpene synthases and their use for production of diterpenes

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10980744

    High density peptide polymers

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10982230

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10980767

    Estrogen receptor ligands, compositions and methods related thereto

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10980847

    Compositions and methods for detecting and treating brain injury associated fatigue and altered cognition (BIAFAC)

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10982221

    Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10982068

    Dendritic macroporous hydrogels prepared by crystal templating

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10980848

    Antimicrobial therapy

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10981951

    Therapeutics for the treatment of glaucoma

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10980841

    Methods and compositions for in vivo induction of pancreatic beta cell formation

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10973812

    Ataxia therapeutic compositions and methods

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10973764

    Neuroprotective liposome compositions and methods for treatment of stroke

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10975355

    Controlled induction of human pancreatic progenitors produces functional beta-like cells

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10975124

    Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10973844

    TALEN-based gene correction

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10975142

    Endotrophin neutralization and use thereof

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10975093

    Fused 1,4-diazepines as BET protein degraders

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10975167

    Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10975166

    Inhibitory antibodies against MMP-14

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10975059

    Small molecule BRD4 modulators for HIV epigenetic regulation

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10975158

    CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10968180

    Piperidine derivatives as HDAC1/2 inhibitors

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10967065

    Compounds for treating biofilm infection

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10968203

    Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10966950

    Use of an RXR agonist in treating HER2+ cancers

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10967062

    Functionalized nanoparticles and methods of use thereof

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10960029

    Devices and methods for umbilical cord processing

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10960051

    Methods of treating dry eye syndrome

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10960071

    Platform for generating safe cell therapeutics

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10959952

    Use of exosomes for the treatment of disease

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10961282

    Variant adeno-associated viruses and methods of using

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10959984

    Methods for treating cancer with RORΞ³ inhibitors

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10953110

    Dual emissive metal nanoparticles as ratiometric pH indicators

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10954192

    Pyrrolomycins and methods of using the same

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10952970

    Use of vitelline protein B as a microencapsulating additive

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10954304

    Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10953098

    Chemical structures for localized delivery of therapeutic agents

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10953113

    Imaging agents and methods of use

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10952980

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.